Abstract: A hot-rolling stand (10) for a hot-rolling mill comprises an adjusting device (12), which is intended for receiving a pair of work rolls (17) and for positioning work rolls (18, 19; 20, 21) of the pair of work rolls (17) in relation to one another to define a roll gap. In order to create a hot-rolling stand (10) that can be adapted as flexibly as possible, the adjusting device (12) is designed to interchangeably accommodate, in the pair of work rolls (17), different roll diameter ranges by means of mutually complementary work rolls (18, 19; 20, 21).

Abstract: A roll stand having work rolls mounted therein. The roll stand has at least one upper mounting rail, which is mounted on the drive-side roll stand frame and oriented in a transverse direction to a rolling line running through the roll stand. In order to be able to keep the assembly space in the roll stand over the rolling line free during rolling—except for a roll change—and still change the roll efficiently, the upper mounting rail is configured to be moved into the rolling line and out of the rolling line, starting from the drive-side roll stand frame.

Abstract: A method for manufacturing control of machining of workpieces in a manufacturing hall that includes providing a plurality of image acquisition devices configured to acquire image sequences of allocated observation areas, identifying an object to be tracked in a first image of a first image sequence using at least one object feature, determining positions of the object feature in images of subsequent image sequences, determining a current position of the object by localizing the object feature in a temporally current image of one of the image sequences, and assigning the position of the object feature in the temporally current image to a current position in the observation area of the image sequence that includes the temporally current image, and integrating the determined current position of the object into the manufacturing control of the hall.

Abstract: The present invention is directed to HER2 antibodies directed against an epitope between amino acids 342-652 of human HER2 for use in the treatment of HER2 related disorders in combination with a second HER2 inhibitor. More specifically the invention relates to methods and uses of MAB270 or antibodies having the same CDRs as MAB270 in combination with trastuzumab or pertuzumab in HER2 positive cancer.

Abstract: A protective device for the needle tube of a syringe, including a housing which can be pivoted on a support base which has an open housing side in the pivot plane, so that the needle tube can be pivoted into the housing after being used for injection and wherein on the housing side, a retaining device is provided for the needle tube which has been pivoted inwards. The invention proposes that in addition to the connection of a film hinge in order to form a pivot axis, the support base and the pivotable housing are additionally connected together via a predetermined breaking point and wherein after being used for injection, the housing can be pivoted back over the destroyed predetermined breaking point.

Abstract: The present invention relates to monoclonal antibodies that specifically bind to human IL-1 R7, or a fragment or derivative thereof or a polypeptide that contain at least a portion of said antibody that is sufficient to confer specific IL-1 R7 binding to the polypeptide. The invention also relates to the use of said antibodies in the treatment of a IL-18 mediated disease and pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention.

Abstract: Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616 The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL

Abstract: The present invention relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The invention further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The present invention also encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Abstract: A device for the needle tube of a syringe includes a housing which can pivot on a carrier element for the needle tube and which has an open housing side in the pivoting plane of the housing such that the needle tube can be swung into the housing in order to be held there after being used for injection. The arrangement of the rear free end of the needle tube in the carrier element enables controlled piercing, of the all of a container that is replaceable in the carrier element.

Abstract: The present invention relates to monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. The invention also relates to the use of an antibody according to the invention in the treatment of a HER-2 mediated disease. The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention, and the use of said composition in the treatment of a HER-2 mediated disease.

Abstract: The present disclosure relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The disclosure further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The disclosure finally encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Abstract: Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616 The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP

Abstract: In the case of a method or an arrangement for the automatic start up of a first communication terminal (EG A, EG B) configured for voice communication on at least one second communication terminal (CL A, CL B) configured for text communication, the voice communication between communication terminals is conveyed via at least one voice communication server (SCS) and the text communication between communication terminals is conveyed via at least one text communication server (TCS). The at least one voice communication server (SCS) and the at least one text communication server (TCS) exchange information via at least one conversion device (GW). The start up of at least one first communication terminal (CL A, CL B) is effected via the at least one text communication server (TCS), the at least one conversion device (GW) and the at least one voice communication server (SCS) to at least one second voice communication terminal (EG A, EG B).

Abstract: A drive system for a motor vehicle includes a separating clutch, a shiftable transmission, a drive machine, and a transmission gear wheel and a clutch device. In a first operating state either the clutch device or the transmission gear wheel is kinematically coupled to the transmission input shaft and in a second operating state both said clutch device and said transmission gear wheel are kinematically coupled in said manner thereto. The drive system comprises a braking device for transmitting a braking force in a non-contact manner in this first operating state from a first part to a second part of the braking device. In that the first part of the braking device is kinematically coupleable to the transmission input shaft and the second part is kinematically coupleable to the transmission gear wheel.

Abstract: The present invention relates to monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. The invention also relates to the use of an antibody according to the invention in the treatment of a HER-2 mediated disease. The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention, and the use of said composition in the treatment of a HER-2 mediated disease.

Abstract: The present disclosure relates to nesting sub-spaces for a machine tool by reading in evaluation criteria for an arrangement of nested sub-spaces, generating sequence data for an arrangement of nested sub-spaces, repeatedly performing a process until the result data exceeds a specified range. The process includes: generating evaluation data by evaluating the sequence data with an evaluation algorithm, generating result data based on a combinatorial logic of the evaluation data with the evaluation criteria, generating calculation data from the sequence data, the evaluation data, and the result data using the evaluation algorithm, generating further sequence data taking into account the calculation data with the evaluation algorithm, and repeating the process until the result data exceeds a specified range. The calculation data acts onto the generation of new sequence data to improve an arrangement of nested sub-spaces with respect to evaluation criteria.

Abstract: A method for operating a rotating-mass device and a rotating mass device of a two-wheeled vehicle are provided. The rotating-mass device includes first and second gyroscopic instruments, each with a cardanically mounted rotating-mass device suitable for generating torque about their respective rotation axes. Pivoting of the rotating-mass devices is coordinated to influence motion of the two-wheeled vehicle about three orthogonal vehicle axes.

Abstract: The present invention relates to monoclonal antibodies that specifically bind to human IL-1 R7, or a fragment or derivative thereof or a polypeptide that contain at least a portion of said antibody that is sufficient to confer specific IL-1 R7 binding to the polypeptide. The invention also relates to the use of said antibodies in the treatment of a IL-18 mediated disease and pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention.

Abstract: Monoclonal antibody that specifically binds the interleukin 1 receptor type 1 (IL-1RAcP), or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616.

Abstract: Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616 The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NF?B activity, useful in treatment of IL-